🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

Recruitingn/aAges 18 Years - 90 YearsAllJasper Gerritsen
NCT06283927 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molecular patient subgroups remains ill-defined. The aim of this study, therefore, is to compare the effects of resection and best oncological treatment for recurrent glioblastoma as a whole and in clinically important subgroups. This study is an international, multicenter, prospective observational cohort study. Recurrent glioblastoma patients will undergo tumor resection or best oncological treatment at a 1:1 ratio as decided by the tumor board. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks after surgery and 2) ove

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥18 years and ≤90 years 2. Tumor recurrence according to the RANO criteria of a previously diagnosed glioblastoma based on the WHO 2021 classification for glioma 3. The tumor is suitable for resection (according to neurosurgeon) 4. Written informed consent Exclusion Criteria: 1. Tumors of the cerebellum, brainstem, or midline 2. Medical reasons precluding MRI (e.g., pacemaker) 3. Inability to give written informed consent 4. Secondary high-grade glioma due to malignant transformation from low-grade glioma 5. Clinical data unavailable for the newly diagnosed setting
💊

What it tests

  • Re-resection
  • Temozolomide
  • Lomustine
  • Re-irradiation
  • Experimental therapy
📍

Where

8 sites
University of California, San Francisco
San Francisco, United States
Massachusetts General Hospital
Boston, United States
University Hospital Leuven
Leuven, Belgium
University Hospital Heidelberg
Heidelberg, Germany
Technical University Munich
Munich, Germany
Erasmus MC
Rotterdam, Netherlands
Medical Center Haaglanden
The Hague, Netherlands
Inselspital Universitätsspital Bern
Bern, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy